Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Ghrelin and Nutritional Status After a Standardized Meal.

2. juni 2026 opdateret af: Medical University of Bialystok

Analysis of Ghrelin Concentration in the Blood Serum of Patients With Different Nutritional Status Following Consumption of a Standarized Meal.

This study evaluated differences in serum concentrations of ghrelin among individuals with varying nutritional status following a standardized meal.

A total of 80 adults were enrolled and stratified by BMI. Fasting and postprandial ghrelin levels were assessed at multiple time points.

Additionally, dietary habits, physical activity, body composition, and resting energy expenditure were evaluated to explore their association with hormonal responses.

Studieoversigt

Status

Afsluttet

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

Study Objectives

1. The primary objectives was to evaluate differences in serum concentrations of ghrelin among patients with varying nutritional status following consumption of standarized meal (cross-over design).

Secondary Objectives

  1. To compare fasting serum concentrations of ghrelin across nutritional status groups.
  2. To assess postprandial changes (60, 120, 1880, and 240 minutes) in ghrelin depending on nutritional status.
  3. To compare fasting versus postpradial ghrelin levels. Methods

Study Population: A total of 80 adults (aged 40-60 years) were enrolled and stratified by BMI into the following groups:

Normal weight (BMI 18.5-24.9) Overweight (BMI 25.0-29.9) Obesity class I (BMI 30.0-34.9) Obesity class II and III (BMI ≥ 35.0) Exclusion criteria included: carbohydrate metabolism disorders, endocrine disorders, renal and/or hepatic failure, gastrointestinal diseases, history of gastroenterological and bariatric surgery, pharmacological treatment or other preparations whose effect on metabolic and hormonal changes is documented or unknown, pregnancy, lactation and other diseases that may affect the obtained results.

Dietary Intake, Physical Activity, and Quality of Life:

Validated questionnaires (including QEB, IPAQ, WHOQOL-BREF, AND TFEQ-R18) were used. Dietary intake was assessed using 24-hour dietary recalls collected over 3 days (2 weekdays and 1 weekend day).

Nutritional Status Assessment: Anthropometric measurements (body weight, height, waist and hip circumference) were obtained, and BMI, WHR, WHtR, and RFM were calculated. Body composition was assessed using dual-energy X-ray absorptiometry (DEXA).

Biochemical Measurements: Fasting blood samples were collected to assess: glucose, insulin, lipid profile, CRP, ALT, AST, uric acid, creatinine, and ghrelin. After ingestion of a standarized isocaloric meal (Nutridrink Standard), additional blood samples were collected at 60, 120, 180, and 240 minutes.

Resting energy Expenditure: REE was measured using indirect calorimetry (Q-NRG+, COSMED).

Statistical Analysis: Data were analyzed using Statistica 13.3 (StatSoft).

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

80

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

  • Polen
    • Poland
      • Bialystok, Poland, Polen, 15-089
        • Medical University of Bialystok

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Voksen

Tager imod sunde frivillige

Ja

Beskrivelse

Inclusion Criteria:

  • women and men aged 40-60

Exclusion Criteria:

  • type I and II diabetes,
  • exacerbated coronary artery disease,
  • endocrine disorders,
  • pregnancy and lactation period,
  • use of hormonal contraception or hormone replacement therapy, steroid therapy, antiretroviral therapy,
  • surgical or pharmacological history obesity treatment,
  • pacemaker

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Andet
  • Tildeling: Ikke-randomiseret
  • Interventionel model: Crossover opgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Normal Body Weight Group
Participants with normal body weight (BMI: 19-24.9 kg/m2)
Andet: Nutridrink Protein
Participants consumed 187.5 mL of the oral nutritional supplement Nutridrink Protein during the study procedure.
Eksperimentel: Overweight Group
Participants with overweight (BMI: 25-29.9 kg/m2)
Andet: Nutridrink Protein
Participants consumed 187.5 mL of the oral nutritional supplement Nutridrink Protein during the study procedure.
Eksperimentel: Obesity I Group
Participants with class I obesity (BMI: 30-34.9 kg/m2)
Andet: Nutridrink Protein
Participants consumed 187.5 mL of the oral nutritional supplement Nutridrink Protein during the study procedure.
Eksperimentel: Obesity II Group
Participants with class II and class III obesity (BMI > 35 kg/m2)
Andet: Nutridrink Protein
Participants consumed 187.5 mL of the oral nutritional supplement Nutridrink Protein during the study procedure.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Postprandial serum ghrelin concentration
Tidsramme: 24 months (analyzes were performed throughout the study period).
Change in serum ghrelin concentration (pg/mL) over 4 hours following standardized meal intake in participants with different nutritional status. Measurements will be assessed at predefined time points postprandially.
24 months (analyzes were performed throughout the study period).

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Hemoglobin concentration
Tidsramme: 24 months (analyzes were performed throughout the study period).
Hemoglobin level (g/dL) measured in fasting blood samples.
24 months (analyzes were performed throughout the study period).
White blood cell count
Tidsramme: 24 months (analyzes were performed throughout the study period).
WBC count (×10⁹/μL) measured in fasting blood samples.
24 months (analyzes were performed throughout the study period).
Platelet count
Tidsramme: 24 months (analyzes were performed throughout the study period).
Platelet count (×10⁹/μL) measured in fasting blood samples.
24 months (analyzes were performed throughout the study period).
Fasting glucose concentration
Tidsramme: 24 months (analyzes were performed throughout the study period).
Glucose level (mg/dL) measured in fasting blood samples.
24 months (analyzes were performed throughout the study period).
Fasting insulin concentration
Tidsramme: 24 months (analyzes were performed throughout the study period).
Insulin level (µIU/mL) measured in fasting blood samples.
24 months (analyzes were performed throughout the study period).
Total cholesterol concentration
Tidsramme: 24 months (analyzes were performed throughout the study period).
Total cholesterol (mg/dl) measured in fasting blood samples.
24 months (analyzes were performed throughout the study period).
C-reactive protein concentration
Tidsramme: 24 months (analyzes were performed throughout the study period).
CRP level (mg/L) measured in fasting blood samples.
24 months (analyzes were performed throughout the study period).
Alanine aminotransferase activity
Tidsramme: 24 months (analyzes were performed throughout the study period).
ALT level (U/L) measured in serum.
24 months (analyzes were performed throughout the study period).
Aspartate aminotransferase activity
Tidsramme: 24 months (analyzes were performed throughout the study period).
AST level (U/L) measured in serum.
24 months (analyzes were performed throughout the study period).
Serum uric acid concentration
Tidsramme: 24 months (analyzes were performed throughout the study period).
Uric acid level (mg/dL).
24 months (analyzes were performed throughout the study period).
Serum creatinine concentration
Tidsramme: 24 months (analyzes were performed throughout the study period).
Creatinine level (μmol/l).
24 months (analyzes were performed throughout the study period).
Total fat mass measured by DEXA
Tidsramme: 24 months (analyzes were performed throughout the study period).
Total fat mass (kg) assessed using dual-energy X-ray absorptiometry (DEXA).
24 months (analyzes were performed throughout the study period).
Body fat percentage measured by DEXA
Tidsramme: 24 months (analyzes were performed throughout the study period).
Total body fat percentage (%) assessed using dual-energy X-ray absorptiometry (DEXA).
24 months (analyzes were performed throughout the study period).
Lean body mass measured by DEXA
Tidsramme: 24 months (analyzes were performed throughout the study period).
Lean body mass (kg) assessed using dual-energy X-ray absorptiometry (DEXA).
24 months (analyzes were performed throughout the study period).
Visceral adipose tissue measured by DEXA
Tidsramme: 24 months (analyzes were performed throughout the study period).
Visceral adipose tissue mass (cm³) assessed using dual-energy X-ray absorptiometry (DEXA).
24 months (analyzes were performed throughout the study period).
Subcutaneous adipose tissue measured by DEXA
Tidsramme: 24 months (analyzes were performed throughout the study period).
Subcutaneous adipose tissue mass (cm³) assessed using dual-energy X-ray absorptiometry (DEXA).
24 months (analyzes were performed throughout the study period).
Android fat percentage measured by DEXA
Tidsramme: 24 months (analyzes were performed throughout the study period).
Android fat percentage (%) assessed using dual-energy X-ray absorptiometry (DEXA).
24 months (analyzes were performed throughout the study period).
Gynoid fat percentage measured by DEXA
Tidsramme: 24 months (analyzes were performed throughout the study period).
Gynoid fat percentage (%) assessed using dual-energy X-ray absorptiometry (DEXA).
24 months (analyzes were performed throughout the study period).
Dietary habits score (QEB questionnaire)
Tidsramme: 24 months (analyzes were performed throughout the study period).
Score from standardized Questionnaire of Eating Behaviour (QEB).
24 months (analyzes were performed throughout the study period).
Cognitive restraint, uncontrolled eating, and emotional eating scores (TFEQ-R18)
Tidsramme: 24 months (analyzes were performed throughout the study period).
Scores for each subscale of Three-Factor Eating Questionnaire (range 0-100; higher score indicates greater expression of trait).
24 months (analyzes were performed throughout the study period).
Hunger and satiety ratings
Tidsramme: 24 months (analyzes were performed throughout the study period).
Visual analogue scale or standardized scale (0-10)
24 months (analyzes were performed throughout the study period).
Physical activity level (IPAQ score)
Tidsramme: 24 months (analyzes were performed throughout the study period).
International Physical Activity Questionnaire (IPAQ) score expressed in MET-minutes/week. Higher values indicate higher physical activity level.
24 months (analyzes were performed throughout the study period).
Quality of life score (WHOQOL-BREF)
Tidsramme: 24 months (analyzes were performed throughout the study period).
WHOQOL-BREF scores for physical, psychological, social, and environmental domains. Scores range 0-100; higher score indicates better quality of life.
24 months (analyzes were performed throughout the study period).
Resting energy expenditure measured by indirect calorimetry
Tidsramme: 24 months (analyzes were performed throughout the study period).
REE measured in kcal/day using indirect calorimetry (Q-NRG+, COSMED).
24 months (analyzes were performed throughout the study period).

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Medical University of Bialystok

Efterforskere

  • Ledende efterforsker: Lucyna Ostrowska, Professor, Department of Dietetics and Clinical Nutrition Medical University of Bialystok

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Generelle publikationer

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

8. april 2025

Primær færdiggørelse (Faktiske)

14. april 2026

Studieafslutning (Faktiske)

14. april 2026

Datoer for studieregistrering

Først indsendt

13. maj 2026

Først indsendt, der opfyldte QC-kriterier

2. juni 2026

Først opslået (Faktiske)

4. juni 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

4. juni 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

2. juni 2026

Sidst verificeret

1. maj 2026

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • B.SUB.24.112
  • AZN.614.1.2024 (Andet bevillings-/finansieringsnummer: Medical University of Bialystok)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

UBESLUTET

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med Nutridrink Protein

Søg i lignende forsøg

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

CROs by country

CROs in Tunisia

Betingelser

Sjældne sygdomme

Narkotikainterventioner

Kosttilskud

Sponsor / samarbejdspartnere

Placeringer

Abonner